WO2006104397A1 - Compositions antagonistes du cuivre - Google Patents

Compositions antagonistes du cuivre Download PDF

Info

Publication number
WO2006104397A1
WO2006104397A1 PCT/NZ2006/000054 NZ2006000054W WO2006104397A1 WO 2006104397 A1 WO2006104397 A1 WO 2006104397A1 NZ 2006000054 W NZ2006000054 W NZ 2006000054W WO 2006104397 A1 WO2006104397 A1 WO 2006104397A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
copper
triethylenetetramine
clo alkyl
composition
Prior art date
Application number
PCT/NZ2006/000054
Other languages
English (en)
Inventor
Garth James Smith Cooper
Original Assignee
Protemix Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corporation Limited filed Critical Protemix Corporation Limited
Publication of WO2006104397A1 publication Critical patent/WO2006104397A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention se rapporte à des compositions pharmaceutiques ayant un ou plusieurs composé(s) antagoniste(s) du cuivre acceptable(s) du point de vue pharmaceutique ou un sel ou promédicament de ces composés pharmaceutiquement acceptable , incluant des antagonistes du cuivre (II), ainsi qu’un agent anti-obésité ou un sel ou promédicament pharmaceutiquement acceptable de ce dernier, des articles, des kits et des dispositifs de délivrance contenant ces compositions, des comprimés, des gélules et des formulations contenant ces compositions, ainsi que des procédés d’utilisation pour le traitement de sujets, y compris d’humains, qui sont atteints de nombreuses maladies, troubles et états pathologiques ou sont exposés à un risque vis-à-vis de ceux-ci.
PCT/NZ2006/000054 2005-03-26 2006-03-27 Compositions antagonistes du cuivre WO2006104397A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66523505P 2005-03-26 2005-03-26
US60/665,235 2005-03-26

Publications (1)

Publication Number Publication Date
WO2006104397A1 true WO2006104397A1 (fr) 2006-10-05

Family

ID=37053606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2006/000054 WO2006104397A1 (fr) 2005-03-26 2006-03-27 Compositions antagonistes du cuivre

Country Status (1)

Country Link
WO (1) WO2006104397A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050720A1 (fr) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Composition pharmaceutique d'orlistat
WO2009080024A1 (fr) * 2007-12-20 2009-07-02 Fertin Pharma A/S Chewing-gum comprimé comprenant un mimétique de l'incrétine
WO2009080032A1 (fr) * 2007-12-20 2009-07-02 Fertin Pharma A/S Chewing-gum comprimé comprenant un petit peptide à action systémique
WO2017142424A1 (fr) * 2016-02-18 2017-08-24 Garth Cooper Traitement de troubles neurodégénératifs
WO2017213524A1 (fr) * 2016-06-10 2017-12-14 Garth Cooper Traitement de troubles neurodégénératifs
EP3318252A1 (fr) * 2016-11-08 2018-05-09 Alpex Pharma SA Comprimé à libération prolongée comprenant un médicament favorisant la perte de poids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058294A1 (fr) * 2003-12-19 2005-06-30 Protemix Corporation Limited Composes antagonistes du cuivre

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058294A1 (fr) * 2003-12-19 2005-06-30 Protemix Corporation Limited Composes antagonistes du cuivre

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AVENELL A. ET AL.: "Systematic review of the long-term effects and economic consequences of treatments for obesity and implication for health improvement", HEALTH TECHNOLOGY ASSESSMENT, vol. 8, no. 21, May 2004 (2004-05-01), pages 1 - 182 *
MUNRO J.F.: "Clinical aspects of the treatment of obesity by drugs: a review", INTERNATIONAL JOURNAL OF OBESITY, vol. 3, no. 2, 1979, pages 171 - 180 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050720A1 (fr) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Composition pharmaceutique d'orlistat
WO2009080024A1 (fr) * 2007-12-20 2009-07-02 Fertin Pharma A/S Chewing-gum comprimé comprenant un mimétique de l'incrétine
WO2009080032A1 (fr) * 2007-12-20 2009-07-02 Fertin Pharma A/S Chewing-gum comprimé comprenant un petit peptide à action systémique
WO2017142424A1 (fr) * 2016-02-18 2017-08-24 Garth Cooper Traitement de troubles neurodégénératifs
WO2017213524A1 (fr) * 2016-06-10 2017-12-14 Garth Cooper Traitement de troubles neurodégénératifs
EP3318252A1 (fr) * 2016-11-08 2018-05-09 Alpex Pharma SA Comprimé à libération prolongée comprenant un médicament favorisant la perte de poids
WO2018087097A1 (fr) 2016-11-08 2018-05-17 Alpex Pharma Sa Comprimé à libération prolongée comprenant un médicament d'amaigrissement
AU2017258853B2 (en) * 2016-11-08 2019-05-16 Alpex Pharma Sa Extended release tablet comprising a weight-loss drug
CN110022868A (zh) * 2016-11-08 2019-07-16 阿尔培斯制药公司 含减肥药的缓释片剂
CN110022868B (zh) * 2016-11-08 2022-09-16 阿尔培斯制药公司 含减肥药的缓释片剂
US11744809B2 (en) 2016-11-08 2023-09-05 Alpex Pharma Sa Extended release tablet comprising a weight-loss drug

Similar Documents

Publication Publication Date Title
US11419831B2 (en) Dosage forms and related therapies
WO2006104401A1 (fr) Compositions antagonistes du cuivre
US20050159364A1 (en) Copper antagonist compounds
JP6581625B2 (ja) 代謝障害を治療するための組成物および方法
ES2487897T3 (es) Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US20060128610A1 (en) Methods of treatment
JP2016504384A (ja) ビグアナイドを含む遅延放出組成物
WO2006104397A1 (fr) Compositions antagonistes du cuivre
TW200924757A (en) Modified absorption formulation of gaboxadol
JP2018087214A (ja) スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
ES2744495T3 (es) Preparación farmacéutica sólida
WO2007055598A1 (fr) Traitement de maladies liées aux mitochondries et amélioration de déficits métaboliques liés à l’âge
WO2006104400A1 (fr) Compositions antagonistes du cuivre
US20090093542A1 (en) Copper antagonist compositions
WO2006104396A1 (fr) Compositions antagonistes du cuivre pre-complexees
WO2006104398A1 (fr) Compositions antagonistes du cuivre
US20090093506A1 (en) Copper antagonist compositions
WO2006104399A1 (fr) Compositions antagonistes du cuivre
WO2006104402A1 (fr) Compositions d'antagonistes du cuivre
NZ539695A (en) Dosage forms and related therapies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06716816

Country of ref document: EP

Kind code of ref document: A1